CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 5 enrolled
Drug / intervention
Folfirinox +1 moredrug
Likely dose
Folfirinox 85 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02128100
NCT02128100Phase 2Completed
CompareCT.gov

The Effect of FOLFIRINOX and Stereotactic Body Radiation Therapy for Locally Advanced, Non-Resectable Pancreatic Cancer

University of Louisville·interventional·Posted May 1, 2014·Updated Mar 5, 2024

In Brief

A Phase 2 clinical trial evaluating Folfirinox and Stereotactic Body Radiation Therapy for Pancreatic Cancer Non-resectable. Completed, enrolled 5 participants across 1 site.

Detailed Summary

This study wants to find out how safe and effective the use of Folfirinox combined with Stereotactic Body Radiation Therapy )(SBRT) is for the treatment of pancreatic cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPancreatic Cancer Non-resectable
CountriesUnited States
CollaboratorsJames Graham Brown Cancer Center

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedMay 1, 2014
Enrollment StartSep 19, 2014
Primary CompletionMar 15, 2021
TodayJul 2, 2026
Enrollment to primary: 6.5 yearsPosted 12.2 years ago

Interventions

Folfirinoxdrug

* Oxaliplatin 85 mg/m² for over 2 hours, * Leucovorin 400n mg/m² for over 2 hours, * Irinotecan 180 mg/m² for over 90 minutes, along with Leucovorin infusion * Fluorouracil 400 mg/m² as a fast infusion over 15 minutes * Fluorouracil 2400 mg/m² as a slow infusion over 46 hours

Stereotactic Body Radiation Therapyradiation

5 treatments of stereotactic ablative radiotherapy (SABR) over the course of two weeks with a minimum of 36 hours in between each treatment.